FDA Grants Rapid Supplemental Approval Expanding Casgevy Gene Therapy to Young Children Aged 2 and Older
On July 1, 2026, the U.S. FDA issued a supplemental approval for Vertex Pharmaceuticals' CRISPR-based gene therapy Casgevy (exagamglogene autotemcel). The decision expands Casgevy's indication to include pediatric patients aged 2 years and older who have either:
- Sickle Cell Disease (SCD) with recurrent vaso-occlusive crises (VOCs)
- Transfusion-Dependent $\beta$-Thalassemia (TDT)
This landmark decision makes Casgevy the first gene therapy approved for young children under the age of 5 with sickle cell disease. Previously, Casgevy was only approved for patients aged 12 and older.
Rapid Regulatory Path Under CNPV Pilot
The supplemental approval was granted in just 53 days from filing. This rapid turnaround was achieved under the FDA Commissioner's National Priority Voucher (CNPV) Pilot Program, designed to expedite reviews of therapies targeting critical pipeline needs and rare pediatric diseases while maintaining rigorous safety and efficacy standards.
Clinical Trial Evidence and Extrapolation
Because children with SCD and TDT face severe long-term complications, including growth impairment and early end-organ damage, early intervention is therapeutically vital. The approval was supported by clinical data in older pediatric cohorts:
- SCD Cohort (Ages 5 to <12): Evaluated in a trial of 11 patients. Of the 8 patients evaluable for efficacy, 100% (8/8) achieved the primary outcome of remaining completely free of severe vaso-occlusive crises (VF12) for at least 12 consecutive months.
- TDT Cohort (Ages 5 to <12): Evaluated in a trial of 15 patients. Of the 9 patients evaluable for efficacy, 89% (8/9) achieved complete transfusion independence for at least 12 consecutive months, with a median duration of transfusion independence of 20.1 months.
- Extrapolation to Ages 2–5: Based on highly consistent product characteristics and robust clinical study data, the FDA granted extrapolation to expand the label1 down to 2 years of age for both conditions.
Safety and Administration
Casgevy is a one-time, autologous gene therapy where the patient’s own stem cells are edited ex vivo using CRISPR/Cas9 to increase fetal hemoglobin (HbF) levels. Before infusion, patients must undergo high-intensity, full myeloablative conditioning chemotherapy.2 The safety profile in younger children was consistent with older cohorts. The most common adverse events included mucositis, febrile neutropenia, and decreased appetite. The product labeling carries warnings for potential neutrophil engraftment failure, delayed platelet engraftment, and the theoretical risk of off-target genome editing.
"Grounded in the scientific evidence that earlier treatment reduces the risk of lasting end-organ damage, making this therapy available to younger patients opens a critical window for intervention and gives these children a meaningful chance at a healthier future." — Megha Kaushal M.D., MSc, Acting Deputy Director of the Office of Therapeutic Products in CBER and pediatric hematologist
-
An instance of Early pediatric label expansion requires extending adult data through consistent biological extrapolation. — Regulators expanded Casgevy to children down to age 2 by extrapolating consistent biological and product parameters from older cohorts. ↩︎
-
An instance of No medical breakthrough can bypass the physical limits of real-world clinical logistics. — This illustrates that despite rapid, landmark regulatory approvals, gene therapies are constrained by severe and intense real-world physical and clinical logistics. ↩︎